貴州百靈(002424.SZ)及華西健康、陳俐娟擬共同以資產對成都賾靈進行增資
格隆匯 11 月 6日丨貴州百靈(002424.SZ)公佈，公司於2019年4月15日與四川華西健康科技有限公司(“乙方”或“華西健康”)、陳俐娟(“丙方”)簽訂《投資協議書》，三方共同投資設立了成都賾靈生物醫藥科技有限公司(“成都賾靈”)，公司持股比例為55%，華西健康持股比例為4.5%，陳俐娟持股比例為40.5%。成都賾靈已於2019年4月29日完成工商註冊登記手續。
2020年11月6日，公司與華西健康、陳俐娟簽訂《投資協議書》。公司擬將持有成都賾靈23.5%的股權(對應認繳出資額人民幣1567萬元，實繳出資額為0元)以人民幣0元的價格轉讓給由陳俐娟或陳俐娟所控制的其他主體。陳俐娟有權將不超過人民幣600萬元的註冊資本(對應認繳出資額人民幣600萬元，實繳出資額為0元)轉讓給公司認可的第三方。
公司以“腫瘤靶向治療藥物GZ50”、“抗血液系統腫瘤藥物注射用甲磺酸普依司他”知識產權(包括專利技術成果)按評估價作價人民幣7334萬元對成都賾靈進行增資。華西健康、陳俐娟共同以“治療自身免疫性疾病炎症性腸病(IBD)和類風濕關節炎(RA)的選擇性JAKs小分子抑制劑藥物”、“治療膿毒症及多發性硬化症的RIPK1/2抑制劑藥物ZL-24”、“靶向核苷酸結合寡聚化結構域樣受體蛋白3(NLRP3)炎性體抑制劑藥物”三個1類創新藥品種及全部知識產權按評估價作價人民幣9000萬元對成都賾靈進行增資，其中，華西健康佔評估價的10%，即人民幣900萬元，陳俐娟佔評估價的90%，即人民幣8100萬元。
上述增資後，成都賾靈股權結構及出資方式：
為進一步適應藥事法規和證券市場的變化，變被動為主動，及早與有優勢資源的研究機構和研究者形成緊密的共同體，促進產學研有效結合，實現資源共享，搭建長期、穩定的戰略合作關係，共同致力於人民健康事業，甲方、乙方及丙方經過前期充分溝通和協商討論，擬共同對成都賾靈進行增資，近一步擴大成都賾靈的研發項目儲備，增強核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
